Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
Date:1/22/2009

IRVINE, Calif., Jan. 22 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive results from the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye disease. Patients treated with ecabet sodium achieved a strong positive trend in the objective sign of Tear Film Break-Up Time (TFBUT) and a positive trend in the objective sign of quantity of tears produced (Schirmer Test). In contrast, there were no trends seen in the placebo group for either objective sign. In addition, there were no trends seen in either group in subjective symptoms as measured by the Ocular Surface Disease Index (OSDI) or patient's worst reported symptom. In Phase II tests where observations are not powered to show statistical significance, strong and positive trends are used as indicators of potential efficacy in subsequent Phase III studies.

"The Phase IIb results from this environmental study add further support to our belief that ecabet sodium has the ability to treat signs and symptoms of dry eye syndrome. Ecabet sodium may provide advantages over other products used to treat dry eye and those that are in development, as we believe ecabet sodium not only improves the quality of tears but also increases the quantity of tears," stated Vicente Anido Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "After reviewing the guidance from and our discussions with the FDA, we believe that by conducting two successful Phase III environmental clinical trials for improvement in signs and two successful Phase III controlled chamber clinical trials for the improvement of symptoms, we should receive marketing approval. In addition, we are expecting results from a Phase II clinical trial studying the potential of a lower strength of Xibrom to treat the signs and symptoms
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
6. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The ... recombinant proteins, is placing renewed emphasis on alternate ... rise as a number of factors are converging ... pharmaceutical makers and their delivery device partners . ... refractory conditions, the growing trend toward self-administration for ...
(Date:5/17/2013)... -- Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) a ... patent-pending technologies poised to redefine how consumers receive energy, medicines, ... business update teleconference and webcast for shareholders and the investment ... PM ET. Fuse Science, Inc. CEO, ... will be joined by Rubin Hanan , ...
(Date:5/17/2013)... 17, 2013  PENTAX Medical, a healthcare industry ... global leader in ultrasound imaging, recently announced renewed ... enable further innovation in the development of Endoscopic ... systems and PENTAX Medical endoscopic portfolio have formed ... EUS systems. This agreement will continue to grow ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3
... of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative forty-five percent ... of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative ...
... Florida and Scripps Research in La ... ... and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. ... Scripps Research,Institute, a non-profit biomedical research organization, today announced,that an agreement ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
(Date:5/19/2013)... Today, Zane Benefits, Inc. published ... insurance . Zane Benefits, which provides comprehensive and ... is the leader in health care reform, ... . , According to Zane Benefits’ website, many ... the value of small business health insurance for ...
(Date:5/19/2013)... Corpus Christi, TX (PRWEB) May 19, 2013 ... home security systems companies. Homeowners who are considering ... options and services of the nation's leading security system ... security systems reviews the best DIY home security ... results. Every year 6Webs.com reviews dozens of home security ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob ... people with fat burning diet plans, training ... Burning Furnace package, people will receive the Fat Burning ... quickly. The Fat Burning Furnace manual includes fat loss ... muscle mass. In addition, this book covers step-by-step instructions, ...
(Date:5/19/2013)... Farming methods have changed many times ... 10,000 years ago. Most recently, the Green Revolution has ... genetically engineered seeds and by applying chemical fertilizers and ... these techniques due to the adverse environmental and health ... surge in interest in organic, sustainable farming practices and ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Vegas Hotel ... is proud to announce the launch it's all new ... the MGM Grand on 5/19/2013. Consumers traveling to Las ... special pricing available on VegasHotelEscapes.com's website. Travelers will be ... beat any competitors price. , Vegas Hotel Escapes specializes ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3
... were women who also received training to manage the ... may seem best at preventing illness rather than treating ... activity could make an immediate difference for people with ... chronic pain syndrome who exercised moderately for four months ...
... University of Virginia clinical psychologists has found that teens who ... to exhibit delinquent behavior in early adulthood than their peers ... study also suggests that early sex may play a role ... adulthood., The finding is published in the current online edition ...
... Terms, quarterly report analyzes the information, needs that drove ... ... third quarter, NEW YORK, Nov. 12 ... ongoing series of quarterly reports intended to shed light on,the most ...
... Company Brings Global U.N. Environmental Initiative to ... its,commitment to sustainability and social responsibility, today ... up their sleeves, grabbed their spades and ... company announced that it has joined the ...
... on Striking Nurses, BECKLEY, W.Va., Nov. 12 ... Health Care (ARH), represented by,the Kentucky and West ... to call public attention to the underhanded and,violent ... their strike,which began Oct. 1. ARH has escalated ...
... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the power ... consumers and businesses, today announced that it,has rescheduled ... report results for its third quarter ended September ... Wednesday, November 14, 2007 and,will host a conference ...
Cached Medicine News:Health News:Exercise Eases Fibromyalgia Symptoms: Study 2Health News:Exercise Eases Fibromyalgia Symptoms: Study 3Health News:Early teen sex may not be a path to delinquency, study shows 2Health News:SearchMedica.com Reveals Top Searches Among Medical Professionals 2Health News:SearchMedica.com Reveals Top Searches Among Medical Professionals 3Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 2Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 3Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 4Health News:Nurses Protest Violent Tactics Against Picketers 2Health News:eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call 2
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Straight shafts with 1 x 2 Elsching style teeth. Wide serrated handle with polished finish....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
Medicine Products: